Cisplatin News and Research

RSS

CRIPTO1 role in TKI resistance elucidated

Overexpression of CRIPTO1 may explain intrinsic tyrosine kinase inhibitor resistance in around 10% of patients with non-small-cell lung cancer and endothelial growth factor receptor mutations, research indicates.

23 Jul 2014

Marker identified for population of renal cancer cells with stem-cell-like features

Researchers have identified a population of clear cell renal cell carcinoma cells positive for the CTR2 marker that possess some stem-cell-like features and are able to induce an angiogenic response in vivo.

22 Jul 2014

Marker identified for population of renal cancer cells with stem-cell-like features

22 Jul 2014

Merck reports results from global EMEND Phase 3 study for CINV prevention in pediatric cancer patients

Merck, known as MSD outside the United States and Canada, today announced results from a global, investigational Phase 3 study to evaluate the safety and efficacy of EMEND (aprepitant) in the prevention of chemotherapy-induced nausea and vomiting (CINV) in pediatric cancer patients, aged 6 months to 17 years.

30 Jun 2014

SCLC tumours replicated in mice from patients' CTCs

Scientists have used circulating tumour cells taken from patients with small-cell lung cancer to grow explant tumours in mice that retain the original’s morphological and genetic characteristics.

20 Jun 2014

Adjuvant chemotherapy and adjuvant radiation recommended for R1 resected cancer patients

A landmark survey of more than 700 specialists provides crucial real-world insight into the treatments most oncologists choose for lung cancer patients whose tumour has been incompletely resected, an expert from the European Society for Medical Oncology (ESMO) says.

11 Jun 2014

Synthetic peptide carrier delivers drugs through blood-brain barrier for cancer treatment

Researchers at Mayo Clinic have demonstrated in a mouse model that their recently developed synthetic peptide carrier is a potential delivery vehicle for brain cancer chemotherapy drugs and other neurological medications. The findings appear in PLOS ONE.

4 Jun 2014

CRS-207 and chemotherapy combination Phase 1b trial data for unresectable MPM presented at ASCO 2014

Aduro BioTech, Inc., a clinical stage biotechnology company, today announced the presentation of safety and efficacy data from a Phase 1b clinical trial of its novel immunotherapy CRS-207 in combination with standard chemotherapy in patients with unresectable malignant pleural mesothelioma.

2 Jun 2014

Investigational drug for advanced bladder cancer shows promise for treatment of certain tumor types

A multi-center phase I study using an investigational drug for advanced bladder cancer patients who did not respond to other treatments has shown promising results in patients with certain tumor types, researchers report.

31 May 2014

Genetic changes can predict which patient will benefit from chemotherapy before bladder cancer surgery

Three genetic changes can predict whether a patient will benefit from chemotherapy before surgery to remove bladder cancer, according to new findings presented by Fox Chase Cancer Center researchers during the 50th Annual Meeting of the American Society of Clinical Oncology.

31 May 2014

FDA approves Cyramza to treat patients with advanced stomach cancer

Based on results of a clinical trial led by Dana-Farber Cancer Institute scientists, the U.S. Food and Drug Administration (FDA) approved a molecularly targeted drug as second-line treatment in advanced stomach cancer that has progressed after standard chemotherapy has failed.

22 Apr 2014

FDA approves molecularly targeted drug as second-line treatment for advanced stomach cancer

Based on results of a clinical trial led by Dana-Farber Cancer Institute scientists, the U.S. Food and Drug Administration approved a molecularly targeted drug as second-line treatment in advanced stomach cancer that has progressed after standard chemotherapy has failed.

22 Apr 2014

Study shows R9-caPep compound blocks PCNA actions in neuroblastoma cells

Neuroblastoma is one of the deadliest childhood cancers, accounting for 15 percent of pediatric cancer deaths. For patients with high-risk neuroblastomas, the five-year survival rate is 40 to 50 percent even with the most rigorous treatments available today.

17 Apr 2014

Amrubicin regimen inferior to irinotecan for extensive SCLC

Irinotecan plus cisplatin remains the gold standard for Japanese patients with extensive small-cell lung cancer, say researchers, after amrubicin plus cisplatin failed to improve survival in their randomised phase III trial.

11 Apr 2014

Researchers find new molecular targets for aggressive brain tumor

Researchers from the Geisel School of Medicine at Dartmouth will present a scientific poster on Tuesday, April 8, 2014 at the American Association of Cancer Researchers conference in San Diego, CA. The research identifies a potential characteristic for predicting outcome in a deadly form of brain cancer known as glioblastoma multiforme.

9 Apr 2014

DelMar presents pre-clinical study data that evaluates activity of VAL-083 in drug-resistant NSCLC

DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") today announced the presentation of new data in a poster entitled, "In vivo efficacy of VAL-083 in the treatment of non-small cell lung cancer." DelMar's data was presented on Sunday, April 6, 2014 during the Novel Cytotoxic Strategies Session at the 105th Annual Meeting of the American Association for Cancer Research (AACR) in San Diego.

8 Apr 2014

Accele Venture Partners co-led $4.1M Series A private equity financing of Otologic Pharmaceutics

Accele Venture Partners, the investing arm of life sciences accelerator Accele Biopharma, Inc., announced today that it has co-led a $4.1 million Series A private equity financing of Otologic Pharmaceutics, Inc. (OPI), a development-stage biopharmaceutical company committed to developing and commercializing novel pharmacological solutions and approaches to treat hearing disorders.

3 Apr 2014

Investigational vaccine reduces number of tumors in mice with lung cancer

Researchers at UC Davis have found that the investigational cancer vaccine tecemotide, when administered with the chemotherapeutic cisplatin, boosted the immune response and reduced the number of tumors in mice with lung cancer.

20 Mar 2014

Hint of survival benefit with bevacizumabpemetrexed maintenance for NSCLC

Updated data from the phase III AVAPERL trial hint that there might be an overall survival benefit of using bevacizumab in combination with pemetrexed as maintenance therapy in patients with advanced nonsmall cell lung cancer.

19 Mar 2014

Bayer and Onyx announce Phase 3 trial evaluating use of NEXAVAR for patients with HCC after local ablation

Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc., an Amgen subsidiary (Nasdaq: AMGN), today announced that a Phase 3 trial evaluating the investigational use of NEXAVAR® (sorafenib) tablets as an adjuvant treatment for patients with hepatocellular carcinoma (HCC), or liver cancer, who had no detectable disease after surgical resection or local ablation, did not meet its primary endpoint of improving recurrence-free survival.

11 Mar 2014

Cisplatin News and Research

CRIPTO1 role in TKI resistance elucidated

Marker identified for population of renal cancer cells with stem-cell-like features

Marker identified for population of renal cancer cells with stem-cell-like features

Merck reports results from global EMEND Phase 3 study for CINV prevention in pediatric cancer patients

SCLC tumours replicated in mice from patients' CTCs

Adjuvant chemotherapy and adjuvant radiation recommended for R1 resected cancer patients

Synthetic peptide carrier delivers drugs through blood-brain barrier for cancer treatment

CRS-207 and chemotherapy combination Phase 1b trial data for unresectable MPM presented at ASCO 2014

Investigational drug for advanced bladder cancer shows promise for treatment of certain tumor types

Genetic changes can predict which patient will benefit from chemotherapy before bladder cancer surgery

FDA approves Cyramza to treat patients with advanced stomach cancer

FDA approves molecularly targeted drug as second-line treatment for advanced stomach cancer

Study shows R9-caPep compound blocks PCNA actions in neuroblastoma cells

Amrubicin regimen inferior to irinotecan for extensive SCLC

Researchers find new molecular targets for aggressive brain tumor

DelMar presents pre-clinical study data that evaluates activity of VAL-083 in drug-resistant NSCLC

Accele Venture Partners co-led $4.1M Series A private equity financing of Otologic Pharmaceutics

Investigational vaccine reduces number of tumors in mice with lung cancer

Hint of survival benefit with bevacizumabpemetrexed maintenance for NSCLC

Bayer and Onyx announce Phase 3 trial evaluating use of NEXAVAR for patients with HCC after local ablation

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News